EMA seeks to ease the reg­u­la­to­ry bur­den on biosim­i­lar de­vel­op­ers, fol­low­ing push by FDA

The Eu­ro­pean Med­i­cines Agency ear­li­er this week pro­posed re­duc­ing the reg­u­la­to­ry re­quire­ments for biosim­i­lar de­vel­op­ers due to what it calls “the ad­vances in the an­a­lyt­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER